CFDA Says Regulatory Reform Needs Market Push: DIA China Meeting
This article was originally published in PharmAsia News
China FDA plans to push reforms by looking to markets for ideas and feedback, delegating tasks to provincial branches, procuring third-party services, and considering a drug review fee increase, says CFDA deputy commissioner Yin Li.
You may also be interested in...
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.